1 Clinical evaluation of the molecular-based BD SARS-CoV-2/Flu for the BD MAXTM System

3 Sonia Paradis, MS, a Elizabeth Lockamy, PhD, a Charles K. Cooper, MD, a Stephen Young, PhD

- 5 ^aBecton, Dickinson and Company, BD Life Sciences Integrated Diagnostic Solutions, 7
- 6 Loveton Circle, Sparks, MD, USA
- ^bTricore Reference Laboratory, 1001 Woodward Place, N.E., Albuquerque, NM, USA
- 9 #To whom correspondence should be addressed:
- 10 Stephen Young, PhD

2

4

8

15

23

- 11 Title: Medical Director of Research and Clinical Trials
- 12 Address: 1001 Woodward Place, N.E. Albuquerque, NM 87102
- 13 Telephone: 505-938-8855
- 14 Email: <u>Steve.Young@Tricore.org</u>
- 16 ##To whom correspondence should be addressed (alternate):
- 17 Charles K. Cooper, MD
- 18 Vice President of Medical Affairs
- 19 Becton, Dickinson and Company, BD Life Sciences Integrated Diagnostic Solutions
- 20 7 Loveton Circle, Sparks MD 21152, USA
- 21 Phone: 410-316-4984
- 22 E-mail: Charles_K_Cooper@bd.com
- 24 **RUNNING TITLE:** SARS-CoV-2, Flu multiplex molecular assay

25 **ABSTRACT** 26 Efficient and accurate assays for the differential diagnosis of COVID-19 and/or influenza (flu) 27 could facilitate optimal treatment for both diseases. Diagnostic performance related to SARS-28 CoV-2 and Flu A/B detection was characterized for the BD SARS-CoV-2/Flu for BD MAXTM 29 System ("MAX SARS-CoV-2/Flu") multiplex assay in comparison with BD BioGx SARS-CoV-30 2 Reagents for BD MAXTM System ("BioGx SARS-CoV-2") and the Cepheid Xpert[®] Xpress 31 Flu/RSV ("Xpert Flu"). Two hundred and thirty-five nasopharyngeal specimens were obtained 32 from external vendors. MAX SARS-CoV-2/Flu had positive percent agreement (PPA) and 33 negative percent agreement (NPA) values for SARS-CoV-2 and Flu A/B that met FDA-EUA 34 acceptance criteria of >95%. 35 36 **KEY WORDS**

BD MAX; COVID-19; SARS-CoV-2; Influenza; multiplex RT-PCR assay

37

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

INTRODUCTION Since the report of the first cluster of COVID-19 cases in December 2019, over 100 million COVID-19 cases and 2 million COVID-19-related deaths worldwide have been reported by the end of January, 2021, and the numbers continue to rise.[1] In the US, more than 23 million COVID-19 cases and over 450,000 COVID-19 deaths have been recorded through mid-Febuary 2021.[2] Although it is not clear how the 2020-2021 influenza season will impact the health care systems, the 2019-2020 flu season resulted in over 38 million cases involving symptomatic illness and approximately 22,000 deaths in the US.[3] Each year, across the globe, there are an estimated 1 billion cases of influenza, of which, 3-5 million are severe cases and 29,000-655,000 lead to influenza-related respiratory deaths.[4] Although current (as of January 2021) [5] influenza activity is low, this virus has the potential of increasing the workload of healthcare workers already overwhelmed by COVID-19. Although COVID-19 and influenza spread through a similar mechanism of transmission and have overlapping symptoms, the isolation length and the therapeutic approach for COVID-19 patients and influenza patients are not uniform.[6] The recommended isolation period after symptoms onset is a minimum of 4-5 days [7] for flu, whereas it is a minimum of 10 days for COVID-19,[8] impacting absenteeism and contact tracing. The impact of anti-viral drug therapy, which has traditionally been used for influenza patients, is not well-understood for patients with COVID-19; therefore, safety concerns may preclude any potential efficacy. A similar concern exists for drugs such as remdesivir and corticosteroids, which have been used to treat COVID-19 patients, but are not approved for use in influenza patients, and may (for example, in the case of

corticosteroids) have negative side effects in influenza patients.[6] Because the coincidence of

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

high numbers of both COVID-19 and influenza cases in 2020-2021 and in future respiratory virus seasons could produce a significant strain on the healthcare system,[6] differential diagnosis of COVID-19 and influenza, will be an important component for proper patient triage, management, and treatment. Molecular diagnostics for the detection of SARS-CoV-2, including real-time polymerase chain reaction (RT-PCR) assays, have played an important role in the detection of SARS-CoV-2 and diagnosis of COVID-19 due to their high sensitivity.[9] Similarly, RT-PCR-based detection of Influenza A/B ("Flu A/B") virus nucleic acid has been established for a number of years and is commonly employed to establish an influenza diagnosis.[10] Due to the expected co-occurrence and potential co-infection of SARS-CoV-2 and Flu A/B, a multiplex RT-PCR assay, for detection all three targets, could help provide faster results and improve patient management and treatment.[11] This report describes the performance of the new BD SARS-CoV-2/Flu assay reagents for BD MAXTM System multiplex assay for detection of SARS-CoV-2 and Flu A/B. The comparator reference methods were the BD BioGx SARS-CoV-2 Reagents for BD MAXTM System and Cepheid Xpert[®] Xpress Flu/RSV. The objective here was to determine the

performance characteristics of the new multiplex BD SARS-CoV-2/Flu assay.

METHODS AND MATERIALS

78

81

91

79 Specimens and assays 80 This study, which was conducted as part of a Food and Drug Administration-Emergency Use Authorization (EUA) submission, included data comparing the BD SARS-CoV-2/Flu for BD 82 MAXTM System ("MAX SARS-CoV-2/Flu;" Becton, Dickinson and Company; BD Life 83 Sciences—Integrated Diagnostics Solutions, Sparks, MD, USA) with reference methods, BD 84 BioGx SARS-CoV-2 Reagents for BD MAXTM System ("BioGx SARS-CoV-2;" Becton, 85 Dickinson and Company; BD Life Sciences—Integrated Diagnostics Solutions, Sparks, MD, USA) and Cepheid Xpert® Xpress Flu/RSV ("Xpert Flu;" Cepheid®, Sunnyvale, CA, USA), for 86 87 detection of SARS-CoV-2 and Flu A/B, respectively. The BioFire® Respiratory 2.1 Panel 88 ("BioFire SARS-CoV-2;" BioFire Diagnostics, Salt Lake City, UT, USA) was used to test 89 specimens for which MAX SARS-CoV-2/Flu and BioGx SARS-CoV-2 provided discrepant results; the cobas[®] Influenza A/B & RSV assay for use on the cobas[®] Liat[®] System ("Liat Flu;" 90 Roche Diagnostics, Indianapolis, IN, USA) was used to test specimens for which MAX SARS-92 CoV-2/Flu and Xpert Flu provided discrepant results. All assays were performed according to 93 each manufacturer's instructions for use. MAX SARS-CoV-2/Flu, BioGx SARS-CoV-2, and 94 BioFire SARS-CoV-2 assays were performed at BD Integrated Diagnostics Solutions; Xpert Flu 95 and Liat Flu assays were performed at TriCore Reference Laboratories. 96 97 Nasopharyngeal specimens for SARS-CoV-2 testing were obtained from New York Biologics, Inc. (Southhampton, NY, USA) and Trans-Hit Bio (Laval, QC, Canada), and nasopharyngeal 98 99 specimens for Flu A/B testing were obtained from New York Biologics, Inc (Table S1). Two 100 hundred and thirty-five (235) nasopharyngeal specimens either in Copan Universal Transport

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

Medium (UTM®) or in BD Universal Viral Transport (UVT) system (maintained at -65° C ~ -80°C), which were collected between November 30, 2019 to September 3, 2020, were obtained from individuals with ages ranging from <5 years of age to >60 years of age (Table 1). The specimens were collected as part of standard of care (SOC) and the frozen de-identified remnants were used for this research. This article was prepared according to STARD guidelines for diagnostic accuracy studies reporting. Data analysis The primary outcome measures for this study were positive and negative percent agreement (PPA and NPA, respectively) point estimates (with 95% confidence interval [95% CI] calculated using the Wilson score method) for the MAX SARS-CoV-2/Flu assay, compared to each respective reference assay. The McNemar test was used for 2x2 classification to test the difference between paired proportions. The calculated difference is that of marginal proportions ([total proportion of SARS-CoV-2, Flu A, or Flu B positives] – [total proportion of positives (for each of the three causes) by clinical diagnosis]). A p-value <0.05 was utilized to distinguish significant differences (note here that a p-value >0.05 indicates only that disagreement between the two diagnostics methods is random). The Cohen's kappa coefficient was utilized to gauge the agreement between two raters (reference and test) to classify results into mutually exclusive categories. $K=(P_0^{-P_0})/1-P_0(<0, 0, and >0)$ indicating agreements worse than, no better or worse than, and better than that expected by chance). Acceptance criteria for the MAX SARS-CoV-2/Flu assay for US FDA-EUA authorization for SARS-CoV-2 was ≥95% for both PPA and NPA. The PPA criteria for Flu A/B was ≥90% (lower bound of the 95%CI ≥80%) and the NPA

- 124 criteria for Flu A/B was ≥95% (lower bound of the 95%CI ≥90%). Only compliant and
- reportable results for both MAX SARS-CoV-2/Flu and comparator assays were included in this
- 126 analysis.

RESULTS

Two hundred and thirty-five (235) specimens were included in this study, from which, three were excluded due to unreportable results from the instrumental faliure. From the remaining 232 specimens, reference method testing for SARS-CoV-2 (BioGx SARS-CoV-2) and Flu A/B (Xpert Flu), resulted in 52 positive SARS-Cov-2 specimens, 59 positive Flu A specimens, and 60 positive Flu B specimens (Table 1). By reference method, 30, 91, and 90 specimens were negative, respectively, for SARS-CoV-2, Flu A, and Flu B. MAX SARS-CoV-2/Flu results were compared to results from each respective reference method to determine PPA and NPA values. MAX SARS-CoV-2/Flu had PPA and NPA values of 96.2% [95%CI: 87.0, 98.9] and 100% [95%CI: 88.7, 100], respectively, for detection of SARS-CoV-2. For Flu A, MAX SARS-CoV-2/Flu had PPA and NPA values of 100% [95%CI: 93.9, 100] and 98.9% [95%CI: 94.0, 99.8], respectively; for Flu B, MAX SARS-CoV-2/Flu had PPA and NPA values of 98.3% [95%CI: 91.1, 99.7] and 100% [95%CI: 95.9, 100], respectively (Table 2).

DISCUSSION

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

The results here show PPA for the MAX SARS-CoV-2/Flu assay with reference assays meet FDA-EUA acceptance criteria for detection of SARS-CoV-2 (96.2%), Flu A (100%; with a lower bound 95%CI of 93.9%), and Flu B (98.3%; with a lower bound 95%CI of 91.1%). Similarly, compared to reference methods, the MAX SARS-CoV-2/Flu assay was associated with NPA values for detection of SARS-CoV-2 (100%), Flu A (98.9%; with a lower bound 95%CI of 94.0%), and Flu B (100%; with a lower bound 95%CI of 95.9%) that all met FDA acceptance criteria. During discordant testing, the MAX SARS-CoV2/Flu assay was in agreement with the third assays (i.e. BioFire SARS-Cov-2 assay and Liat Flu assay) for both SARS-CoV-2 negative results and for the Flu A positive result by the MAX SARS-CoV-2/Flu assay. For Flu B, the Liat Flu assay agreed with the Xpert Flu assay negative result. However, all discrepant results were associated with high Ct values (ranging from 37.8 to 39.5). The MAX SARS-CoV-2 showed 100% PPA in specimens with reference method results associated with Ct values ≤30 (Table S2). Thus, with its high PPA and NPA for SARS-CoV-2, Flu A, and Flu B, this multiplex assay should reduce specimen collection time and the amount of supplies and reagents necessary to test for both COVID-19 and Flu. Different approaches are currently available for the detection of SARS-CoV-2 and Flu A/B for the diagnosis of both COVID-19 and influenza, respectively. [10, 12] Although culture-based assays were originally utilized to establish an influenza diagnosis, RT-PCR-based technology for diagnosis of influenza currently represents the laboratory method of choice due to its relatively high analytic and clinical sensitivity, as well as short turn-around time.[13] Likewise, RT-PCRbased assays appear to have higher sensitivity for detection for SARS-CoV-2 compared to

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

culture-based assays.[14] Rapid testing, such as immunochromatic assays used to detect viral antigen, have been developed for detection of both SARS-CoV-2 and Flu A/B.[9, 10] Although rapid tests carry advantages, including decreased time-to-result and ease of implementation in decentralized health care settings, RT-PCR-based assays have increased analytical sensitivity compared to rapid tests.[10] Ultimately, multiple factors should be considered before determining which strategy should be employed. For example, hospitals and their associated laboratory partners, which have established a streamlined workflow and a relatively fast turnaround-time, can effectively employ RT-PCR-based assays—especially for patients admitted and managed according to their symptoms. This strategy carries the benefit of high sensitivity and the ability to rule out etiologic agents with a high degree of assurance. If the coincidence of high numbers of both COVID-19 and influenza cases occurs during flu seasons, differential diagnosis for the appropriate therapeutic approach could be a challenging feat. Although COVID-19 and influenza spread through a similar transmission mechanism and have overlapping symptomology, specific differences between the diseases do exist. For example, COVID-19 seems to involve a longer time to symptom onset than influenza, and may cause more severe illness in vulnerable populations once symptoms develop.[15] Also, the therapeutic approach for COVID-19 patients and influenza patients is not uniform. The impact of blanket anti-viral drug, which has traditionally been used for influenza patients, is not established as a treatment for SARS-CoV-2-positive individuals. Therefore, safety concerns may preclude any potential efficacy. A similar problem exists for drugs such as remdesivir and corticosteroids.[6] Both medications have been used to treat COVID-19 patients, but are not approved for use in influenza patients, and may (in the case of corticosteroids) have adverse side

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

effects in influenza patients. Distinguishing the diagnosis of COVID-19 and influenza, therefore, will be an important component for proper patient triage, management, and treatment. Limitations This research was conducted by using materials obtained from pre-selected frozen remnants, received after routine care. A study involving prospective collection would better inform on the positive and negative predictive values of the assay. Conclusions The MAX SARS-CoV-2/Flu assays met US FDA-EUA acceptance criteria for SARS-CoV-2 and Flu A/B detection. Dual detection of the etiologic agents causing COVID-19 and influenza will allow differentiation for those exhibiting common symptoms between the two diseases. This assay should help optimize patient management by decreasing the time and resources required for dual testing. Ultimately, the dual detection method should facilitate an informed decision by physicians on the appropriate treatment for patients exhibiting similar symptoms between the two diseases.

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

ACKNOWLEDGEMENTS We thank the National Institute of Infectious Diseases, Japan, for providing VeroE6TMPRSS2 cells. We also thank Karen Eckert and Karen Yanson (Becton, Dickinson and Company, BD Life Sciences – Integrated Diagnostic Solutions) for their input on the study logistics and content of this manuscript. We thank Yu-Chih Lin and Devin Gary for the editorial assistance. We thank Stanley Chao, Aojun Li, and Yongqiang Zhang (Becton, Dickinson and Company, BD Life Sciences – Integrated Diagnostic Solutions) for statistical support. The individuals acknowledged here have no additional funding or additional compensation to disclose. We are grateful to the study participants who allowed this work to be performed. **AUTHOR CONTRIBUTIONS** All authors contributed to the interpretation of the data, critically revised the manuscript for important intellectual content, approved the final version to be published, and agree to be accountable for all aspects of the work. **FUNDING** This study was funded by Becton, Dickinson and Company; BD Life Sciences—Integrated Diagnostics Solutions. Non-BD employee authors received research funds to support their work for this study. POTENTIAL CONFLICTS OF INTEREST The authors disclose the following conflicts of interest: SP, EL, and CKC are employees of Becton, Dickinson and Company; SY, None.

REFERENCES

226

- 1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
- Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the
- 229 Chinese Center for Disease Control and Prevention. JAMA **2020**; 323:1239-42.
- 230 2. Johns Hopkins University and Medicine, Coronavirus Resource Center. Mortality Analyses.
- https://coronavirus.jhu.edu/data/mortality. 2020.
- 3. Prevention CfDCa. Estimated Influenza Illness, Medical Visits, Hospitalizations, and Deaths
- in the United States-2019-2020 Influenza Season. https://www.cdc.gov/flu/about/burden/2019-
- 234 2020.html. 2020.
- 4. Global influenza strategy 2019-2030. Geneva: World Health Organization; 2019. Licence: CC
- 236 BY-NC-SA 3.0 IGO.
- Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
- 5. World Helath Organization. Influenza Update 383. Accessed December 28, 2020.
- 239 https://www.who.int/influenza/surveillance monitoring/updates/latest update GIP surveillance/
- 240 en/.
- 6. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus research **2020**;
- 242 288:198114-.
- 7. Centers for Disease Control. Stay at home when you are sick. Accessed December 28, 2020.
- 244 https://www.cdc.gov/flu/business/stay-home-when-
- sick.htm#:~:text=Individuals%20with%20suspected%20or%20confirmed,3%20days%20of%20t
- heir%20illness.
- 247 8. Centers for Disease Control. Options to reduce quarantine for contacts of persons with SARS-
- 248 CoV-2 infection using symptom monitoring and diagnostic testing. Accessed December 28,
- 249 2020. https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-options-to-reduce-
- 250 quarantine.html.
- 9. Cheng MP, Papenburg J, Desjardins M, et al. Diagnostic Testing for Severe Acute Respiratory
- 252 Syndrome–Related Coronavirus 2. Annals of Internal Medicine **2020**; 172:726-34.

- 253 10. Vemula SV, Zhao J, Liu J, Wang X, Biswas S, Hewlett I. Current Approaches for Diagnosis
- of Influenza Virus Infections in Humans. Viruses **2016**; 8:96-.
- 255 11. Rubin R. What Happens When COVID-19 Collides With Flu Season? JAMA **2020**; 324:923-
- 256 5.
- 257 12. La Marca A, Capuzzo M, Paglia T, Roli L, Trenti T, Nelson SM. Testing for SARS-CoV-2
- 258 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro
- diagnostic assays. Reprod Biomed Online **2020**; 41:483-99.
- 260 13. Centers for Disease Control. Influenza (Flu). Accessed December 16, 2020.
- 261 https://www.cdc.gov/flu/professionals/diagnosis/overview-testing-methods.htm.
- 262 14. Pekosz A. Antigen-based testing but not real-time PCR correlates with SARS-CoV-2 virus
- culture. (In Press). Clinical Infectious Diseases **2021**.
- 264 15. Centers for Disease Control. Similarites and differences between Flu and COVID-19.
- Accessed December 28, 2020. https://www.cdc.gov/flu/symptoms/flu-vs-
- 266 covid19.htm#:~:text=Flu%20viruses%20can%20cause%20mild,signs%20and%20symptoms%20
- 267 listed%20above.&text=COVID%2D19%20seems%20to%20cause,loss%20of%20taste%20or%2
- 268 <u>0smell</u>.

Table 1. SARS-CoV-2 and influenza positivity by reference method or MAX SARS-CoV-2/Flu across age groups

	Reference			BD MAX SARS-CoV-2/Flu		
Age group	SARS-CoV-2 n (%)	Influenza A n (%)	Influenza B n (%)	SARS-CoV-2 n (%)	Influenza A n (%)	Influenza B n (%)
≤5 years 21.6% (n=50)	0 (0.0)	19 (32.2)	13 (21.7)	0 (0.0)	19 (31.7)	13 (22.0)
6-21 years 19.8% (n=46)	0 (0.0)	12 (20.3)	26 (43.3)	0 (0.0)	12 (20.0)	26 (44.1)
22-59 years 41.8% (n=97)	39 (75.0)	16 (27.1)	16 (26.7)	37 (74.0)	17 (28.3)	15 (25.4)
≥60 years 16.8% (39)	13 (25.0)	12 (20.3)	5 (8.3)	13 (26.0)	12 (20.0)	5 (8.5)
Overall (N=232) ^a	52	59	60	50	60	59

^aCompliant and reportable for MAX and comparator assays.

Table 2. Performance of the MAX SARS-CoV-2/Flu assay for detection of SARS-CoV-2, Flu A and Flu B compared to reference

	SARS-CoV2 ^{a,c}	Flu A ^{b,c}	Flu B ^{b,c}
PPA	96.2% [87.0%, 98.9%]	100% [93.9%, 100%]	98.3% [91.1%, 99.7%]
NPA	100% [88.7%, 100%]	98.9% [94.0%, 99.8%]	100% [95.9%, 100%]
MAX (+) / Ref (+)	50	59	59
MAX (+) / Ref (-)	0	1	0
MAX (-) / Ref (+)	2	0	1
MAX (-) / Ref (-)	30	90	90
kappa	0.948	0.986	0.986

Abbreviations: PPA, positive percent agreement; NPA, negative percent agreement

^aReference method was the BioGx SARS-CoV-2 RT-PCR assay.

^bReference method was the Xpert Flu RT-PCR assay.

 $^{^{}c}$ A statistically significant difference (via McNemar's test on paired proportions was not observed for MAX SARS-CoV-2/Flu for detection of SARS-CoV-2 (-2.4 [95% CI: -5.8, 0.0]; p=0.500), Flu A (0.67 [95% CI: -0.64, 1.97]; p=1.000), or Flu B (-0.67 [95% CI: -1.97, 0.64]; p=1.000).